Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure

Journal of Urology

Volumn 190, Issue 5, 2013, Pages 1686-1691

  Sternberg, Itay A ^a   Dalbagni, Guido ^a   Chen, Ling Y ^a   Donat, Sherri M ^a   Bochner, Bernard H ^a   Herr, Harry W ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

BCG vaccine; Gemcitabine; Treatment failure; Urinary bladder; Urinary bladder neoplasms

Indexed keywords

BCG VACCINE; GEMCITABINE; INTERFERON; MITOMYCIN;

ADULT; AGED; ARTICLE; BCG VACCINATION; BLADDER NECK STENOSIS; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER SPECIFIC SURVIVAL; CANCER SURGERY; CANCER SURVIVAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED STUDY; CYSTECTOMY; DEATH; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSURIA; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEMATURIA; HUMAN; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIMODALITY CANCER THERAPY; NAUSEA; NON MUSCLE INVASIVE BLADDER CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; RECURRENCE FREE SURVIVAL; RECURRENT CANCER; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT RESPONSE; URINARY TRACT INFECTION; URINARY URGENCY;

EID: 84888640688     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2013.04.120     Document Type: Article

References (23)

1. Babjuk M, Oosterlinck W, Sylvester R et al: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011; 59: 997.
2. Sylvester RJ, Brausi MA, Kirkels WJ et al: Long-term efficacy results of EORTC Genito- Urinary Group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 2010; 57: 766.
3. Zlotta AR, Fleshner NE and Jewett MA: The management of BCG failure in non-muscleinvasive bladder cancer: an update. Can Urol Assoc J, suppl., 2009; 3: S199.
4. Lerner SP, Tangen CM, Sucharew H et al: Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer. Urol Oncol 2009; 27: 155.
5. Barlow LJ, Seager CM, Benson MC et al: Novel intravesical therapies for non-muscle-invasive bladder cancer refractory to BCG. Urol Oncol 2010; 28: 108.
6. Yates DR and Roupret M: Contemporary management of patients with high-risk nonmuscle- invasive bladder cancer who fail intravesical BCG therapy. World J Urol 2011; 29: 415.
7. Dash A, Pettus JA 4th, Herr HW et al: A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer 2008; 113: 2471.
8. Jin JO, Lehmann J, Taxy J et al: Phase II trial of adjuvant gemcitabine plus cisplatin-based chemotherapy in patients with locally advanced bladder cancer. Clin Genitourin Cancer 2006; 5: 150.
9. Lorusso V, Pollera CF, Antimi M et al: A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer 1998; 34: 1208.
10. Meliani E, Lapini A, Serni S et al: Gemcitabine plus cisplatin in adjuvant regimen for bladder cancer. Toxicity evaluation. Urol Int 2003; 71: 37.
11. Scosyrev E, Messing EM, van Wijngaarden E et al: Neoadjuvant gemcitabine and cisplatin chemotherapy for locally advanced urothelial cancer of the bladder. Cancer 2012; 118: 72.
12. Shelley M, Cleves A, Wilt TJ et al: Gemcitabine for unresectable, locally advanced or metastatic bladder cancer. Cochrane Database Syst Rev 2011; 4: CD008976.
13. Dalbagni G, Russo P, Sheinfeld J et al: Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder. J Clin Oncol 2002; 20: 3193.
14. Dalbagni G, Russo P, Bochner B et al: Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder. J Clin Oncol 2006; 24: 2729.
15. Lerner SP, Schoenberg MP and Sternberg CN: Textbook of Bladder Cancer. Abingdon, United Kingdom: Taylor & Francis 2006.
16. Witjes JA, van der Heijden AG, Vriesema JL et al: Intravesical gemcitabine: a phase 1 and pharmacokinetic study. Eur Urol 2004; 45: 182.
17. Gontero P, Casetta G, Maso G et al: Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC). Eur Urol 2004; 46: 339.
18. Bartoletti R, Cai T, Gacci M et al: Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study. Urology 2005; 66: 726.
19. Serretta V, Galuffo A, Pavone C et al: Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: Phase I-II study on marker lesions. Urology 2005; 65: 65.
20. Laufer M, Ramalingam S, Schoenberg MP et al: Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study. J Clin Oncol 2003; 21: 697.
21. Bohle A, Leyh H, Frei C et al: Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo-controlled phase III multicentre study. Eur Urol 2009; 56: 495.
22. Skinner EC, Goldman B, Sakr WA et al: SWOG S0353: Phase II trial of intravesical gemcitabine in patients with non-muscle invasive bladder cancer who recurred following at least two prior courses of BCG. Presented at annual meeting of American Urological Association, Atlanta, Georgia, May 19-23, 2012, abstract 1666.
23. Huguet J, Crego M, Sabate S et al: Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. Eur Urol 2005; 48: 53.